Treatment of intrahepatic cholestatic diseases
Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
1. A method of treating Alagille syndrome by administering to a subject in need thereof a therapeutically effective amount of a compound that is (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof.
2. The method of claim 1 where the compound is administered orally.
3. The method of claim 1 where the daily dose of the compound is 20-200 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid.
4. The method of claim 3 where the daily dose of the compound is 50-100 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid.
5. The method of claim 1 where the compound is administered once/day.
6. A method of treating Alagille syndrome by orally administering to a subject in need thereof a therapeutically effective amount of a compound that is (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L -lysine dihydrate salt.
7. The method of claim 6 where the daily dose of the compound is 20-200 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid.
8. The method of claim 7 where the daily dose of the compound is 50-100 mg, when the dose is calculated as (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid.
9. The method of claim 6 where the compound is administered once/day.